A new study suggests that some of the hearing loss caused by noise exposure can be reversed with drugs.
Susan YoungFollow @twitterapi
I’m the biomedicine editor for MIT Technology Review. I look for stories where technology stands to improve human health or advance our understanding of the human condition.
I joined MIT Technology Review in March 2012 after a brief stint in the Washington, D.C., news bureau of the scientific journal Nature. Before I ventured to the East Coast, I spent several years in the San Francisco Bay Area as a doctoral student in molecular biology and one whirlwind year in science-writing boot camp in Santa Cruz.
In California, I wrote for the Stanford University press offices, the Multiple Sclerosis Discovery Forum, and the Salinas Californian newspaper. I grew up in a small town in eastern Texas, surrounded by bird song, rolling cattle fields, and lanky pine trees. When I’m not exploring health tech, you will probably find me cooking or giggling over an exceptional LOLcat.
Susan Young's Stories
A modification to existing LEDs based on firefly abdomens can boost the brightness of the light source.
Many new fitness-tracking devices are on display at the Consumer Electronics Show in Las Vegas.
It’s hard to get straightforward health guidance from personal genome tests, which are banned in some places. But one way to make them more meaningful is to let more people buy them.
In 2012, genomics tiptoed into the doctor’s office, gene therapy rose again, and man and machine united.
Self-trackers are turning their attention to the microbial menageries found on, and in, the human body.
The chemical-sniffing setup will send data to the Web so doctors and patients can get a better sense of what causes attacks.
A compound derived from a toxin from scorpion venom could help neurosurgeons differentiate between healthy and cancerous brain tissue.
With twice as many electrodes in her brain as previous study participants, a paralyzed woman can move a robotic arm with unprecedented flexibility.
By mimicking genetic variation in people with naturally low levels of cholesterol, drug developers are hoping to create a new drug.